Om

Annexin Pharmaceuticals AB is a clinical-stage Swedish biotechnology company developing ANXV, a recombinant human Annexin A5 protein for treating diseases associated with vascular damage and inflammation. The company focuses on ophthalmology and oncology, targeting retinal vein occlusion (RVO), diabetic retinopathy (DR), and cancer indications. Its key product candidate ANXV is being evaluated in Phase 2 clinical studies and is designed to repair cells, reduce inflammation, and improve vascular function. The company operates as a single biotechnology segment. Geographic activity is currently concentrated in the USA, UK, and Sweden through clinical development programs.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I ANNEXIN PHARMACEUTICALS MED ENDAVU: Køb Annexin Pharmaceuticals ($ANNX) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Annexin Pharmaceuticals, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.